<DOC>
	<DOCNO>NCT02103049</DOCNO>
	<brief_summary>In kidney transplant patient atherosclerosis process accelerate even asymptomatic patient . This mainly consequence immunosuppressive therapy . Dyslipidemia treat statin low dos high dos lead rhabdomyolysis therefore contraindicate . As second lipid lower agent commonly ezetimibe use . The investigator hypothesise ezetimibe second lipid lower drug kidney transplant patient lower LDL cholesterol additional 10 per cent .</brief_summary>
	<brief_title>The Impact Ezetimibe Biochemical Markers Cardiovascular Risk Kidney Transplant Patients</brief_title>
	<detailed_description>In addition observe lipid profile investigator intend look pathophysiological effect ezetimibe , influence oxidative stress , endothelial function inflammatory biochemical marker .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>LDL &gt; 2.5 mM , Already treat statin , Stable renal function various GFR , Men woman older 18 year , Signed informed consent . Acute heart disease heart disease last 3 month , kidney graft failure , active systemic inflammatory disease , active malignant disease , chronic diarrhea malabsorption , transaminase increase &gt; 3 fold , creatin kinase increase &gt; 5 fold , hypersensitivity reaction , active peptic ulcer disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>